Back to Search
Start Over
Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
- Source :
- International Journal of Clinical Practice, International journal of clinical practice
- Publication Year :
- 2009
- Publisher :
- Blackwell Publishing Ltd, 2009.
-
Abstract
- Aims: To evaluate the efficacy and tolerability of flexible-dose fesoterodine in subjects with overactive bladder (OAB) who were dissatisfied with previous tolterodine treatment. Methods: This was a 12-week, open-label, flexible-dose study of adults with OAB (¡Ý 8 micturitions and ¡Ý 3 urgency episodes per 24 h) who had been treated with tolterodine (immediate- or extended-release) for OAB within 2 years of screening and reported dissatisfaction with tolterodine treatment. Subjects received fesoterodine 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on the subject's and physician's subjective assessment of efficacy and tolerability. Subjects completed 5-day diaries, the Patient Perception of Bladder Condition (PPBC) and the Overactive Bladder Questionnaire (OAB-q) at baseline and week 12 and rated treatment satisfaction at week 12 using the Treatment Satisfaction Question (TSQ). Safety and tolerability were assessed. Results: Among 516 subjects treated, approximately 50% opted for dose escalation to 8 mg at week 4. Significant improvements from baseline to week 12 were observed in micturitions, urgency urinary incontinence episodes, micturition-related urgency episodes and severe micturition-related urgency episodes per 24 h (all p < 0.0001). Approximately 80% of subjects who responded to the TSQ at week 12 reported satisfaction with treatment; 38% reported being very satisfied. Using the PPBC, 83% of subjects reported improvement at week 12 with 59% reporting improvement ¡Ý 2 points. Significant improvements from baseline (p < 0.0001) exceeding the minimally important difference (10 points) were observed in OAB-q Symptom Bother and Health-Related Quality of Life (HRQL) scales and all four HRQL domains. Dry mouth (23%) and constipation (5%) were the most common adverse events; no safety issues were identified. Conclusion: Flexible-dose fesoterodine significantly improved OAB symptoms, HRQL, and rates of treatment satisfaction and was well tolerated in subjects with OAB who were dissatisfied with prior tolterodine therapy.
- Subjects :
- Adult
Male
medicine.medical_specialty
media_common.quotation_subject
Urology
Urination
urologic and male genital diseases
Medical Records
Young Adult
Patient satisfaction
Quality of life
Surveys and Questionnaires
medicine
Fesoterodine
Humans
Benzhydryl Compounds
media_common
Aged
Aged, 80 and over
Original Paper
Dose-Response Relationship, Drug
business.industry
Urinary Bladder, Overactive
Antimutagenic Agents
Urinary Incontinence, Urge
General Medicine
Middle Aged
medicine.disease
humanities
female genital diseases and pregnancy complications
Surgery
Clinical trial
Treatment Outcome
Tolerability
Overactive bladder
Patient Satisfaction
Quality of Life
Female
Tolterodine
Human medicine
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 17421241 and 13685031
- Volume :
- 63
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- International Journal of Clinical Practice
- Accession number :
- edsair.doi.dedup.....6d33f10d5c8d2f99b4cd17a8d5f32cd3